AVTX
AVTX
NASDAQ · Biotechnology

Avalo Therapeutics Inc

$16.60
+1.67 (+11.19%)
As of Apr 1, 2:16 PM ET ·
Financial Highlights (FY 2025)
Revenue
35.20M
Net Income
7.89M
Gross Margin
58.1%
Profit Margin
22.4%
Rev Growth
-4.5%
D/E Ratio
0.47
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 58.1% 58.1% 58.1%
Operating Margin 21.8% 21.6% 19.4%
Profit Margin 22.4% 22.3% 22.4%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 35.20M 36.29M 36.66M
Gross Profit 20.45M 21.09M 21.30M
Operating Income 7.67M 7.82M 7.11M
Net Income 7.89M 8.09M 8.22M
Gross Margin 58.1% 58.1% 58.1%
Operating Margin 21.8% 21.6% 19.4%
Profit Margin 22.4% 22.3% 22.4%
Rev Growth -4.5% +16.8% -1.1%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 40.58M 45.39M 52.32M
Total Equity 87.21M 96.06M 95.40M
D/E Ratio 0.47 0.47 0.55
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 9.70M 9.50M 9.77M
Free Cash Flow 3.72M 4.67M 3.24M